Jpmorgan Chase & CO Nektar Therapeutics Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nektar Therapeutics stock. As of the latest transaction made, Jpmorgan Chase & CO holds 913,300 shares of NKTR stock, worth $849,369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
913,300
Previous 307,243
197.26%
Holding current value
$849,369
Previous $380,000
212.37%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding NKTR
# of Institutions
145Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$14.8 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$12.2 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$8.74 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$8.56 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $174M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...